**SUPPLEMENTARY TABLE 1**: **Summary of Vaccination Details - Safety Population (N=1290)**

| **Vaccination** | **BE-PCV14(N=645)** | **Prevenar 13(N=645)** | **Overall(N=1290)** |
| --- | --- | --- | --- |
| BCG | 645 (100.0%) | 645 (100.0%) | 1290 (100.0%) |
| Hepatitis-B | 643 (99.7%) | 644 (99.8%) | 1287 (99.8%) |
| Polio# | 645 (100.0%) | 645 (100.0%) | 1290 (100.0%) |
| DTwP-HepB-Hib (Pentavalent) # | 645 (100.0%) | 645 (100.0%) | 1290 (100.0%) |
| **Note:**Percentage were calculated with respective column header count as denominator.N: Sample Size.#Concomitantly given along with PCV14 vaccine |

**SUPPLEMENTARY TABLE 2: Summary of local, solicited systemic and unsolicited AEs by SOC and PT**

| **SOC/PT****N1 (%) [95% CI] n** | **BE-PCV14(N=645)** | **Prevenar 13(N=645)** |
| --- | --- | --- |
| Overall | 137 (21.2%) [18.14:24.60] 235 | 144 (22.3%) [19.17:25.74] 251 |
| General Disorders And Administration Site Conditions | 137 (21.2%) [18.14:24.60] 235 | 144 (22.3%) [19.17:25.74] 251 |
|  Injection Site Erythema | 33 (5.1%) [3.55:7.11] 38 | 36 (5.6%) [3.94:7.64] 44 |
|  Injection Site Induration | 9 (1.4%) [0.64:2.63] 13 | 13 (2.0%) [1.08:3.42] 18 |
|  Injection Site Pain | 93 (14.4%) [11.80:17.37] 133 | 98 (15.2%) [12.51:18.20] 131 |
|  Injection Site Swelling | 44 (6.8%) [5.00:9.05] 51 | 48 (7.4%) [5.54:9.75] 58 |
|

|  |
| --- |
| **Note:** Percentages were calculated using column header count as denominator.95% CI were calculated by Clopper -Pearson Method. N1: Subject Count, N: Sample Size, n: Event Count**General Note:**•   All AE's were represented as: Subject count (Percentage of subjects) [95% CI] Event Count. |

 |

**SUPPLEMENTARY TABLE 3: Summary of Solicited Systemic AEs by SOC & PT**

| **Reported Term****N1 (%) [95% CI] n** | **BE-PCV14(N=645)** | **Prevenar 13(N=645)** |
| --- | --- | --- |
| Overall | 70 (10.9%) [8.56:13.51] 118 | 63 (9.8%) [7.59:12.32] 101 |
| Gastrointestinal Disorders | 8 (1.2%) [0.54:2.43] 11 | 5 (0.8%) [0.25:1.80] 8 |
|  Diarrhoea | 6 (0.9%) [0.34:2.01] 8 | 2 (0.3%) [0.04:1.12] 3 |
|  Vomiting | 3 (0.5%) [0.10:1.35] 3 | 4 (0.6%) [0.17:1.58] 5 |
| General Disorders And Administration Site Conditions | 64 (9.9%) [7.73:12.49] 94 | 58 (9.0%) [6.90:11.47] 81 |
|  Irritability Postvaccinal | 25 (3.9%) [2.52:5.67] 41 | 21 (3.3%) [2.03:4.93] 31 |
|  Pyrexia | 42 (6.5%) [4.73:8.70] 53 | 40 (6.2%) [4.47:8.35] 50 |
| Metabolism And Nutrition Disorders | 8 (1.2%) [0.54:2.43] 9 | 6 (0.9%) [0.34:2.01] 10 |
|  Decreased Appetite | 8 (1.2%) [0.54:2.43] 9 | 6 (0.9%) [0.34:2.01] 10 |
| Nervous System Disorders | 2 (0.3%) [0.04:1.12] 4 | 1 (0.2%) [0.00:0.86] 2 |
|  Somnolence | 2 (0.3%) [0.04:1.12] 4 | 1 (0.2%) [0.00:0.86] 2 |
|

|  |
| --- |
| **Note:** Percentages were calculated using column header count as denominator.95% CI were calculated by Clopper -Pearson Method. N1: Subject Count, N: Sample Size, n: Event Count**General Note:**• All AE's were represented as: Subject count (Percentage of subjects) [95% CI] Event Count.• Solicited Local and Systemic AEs were recored during 7 days (Day 0 – Day 6) after each dose. |

 |

**SUPPLEMENTARY TABLE 4: Summary of Unsolicited Systemic AEs by SOC & PT**

| **SOC/PT,N1 (%) [95% CI] n** | **BE-PCV14(N=645)** | **Prevenar 13(N=645)** |
| --- | --- | --- |
| Overall | 2 (0.3%) [0.04:1.12] 2 | 1 (0.2%) [0.00:0.86] 1 |
| Gastrointestinal Disorders | 1 (0.2%) [0.00:0.86] 1 | 0 (0.0%) [NE] 0 |
|  Abdominal Pain | 1 (0.2%) [0.00:0.86] 1 | 0 (0.0%) [NE] 0 |
| General Disorders And Administration Site Conditions | 0 (0.0%) [NE] 0 | 1 (0.2%) [0.00:0.86] 1 |
|  Pyrexia | 0 (0.0%) [NE] 0 | 1 (0.2%) [0.00:0.86] 1 |
| Respiratory, Thoracic And Mediastinal Disorders | 1 (0.2%) [0.00:0.86] 1 | 0 (0.0%) [NE] 0 |
|  Cough | 1 (0.2%) [0.00:0.86] 1 | 0 (0.0%) [NE] 0 |
| **Note:** Percentages were calculated using column header count as denominator.95% CI was calculated by Clopper-Pearson Method.N1: Subject Count, N: Sample Size, n:Event Count.**General Note:**•  All AE's were represented as: Subject count (Percentage of subjects) [95% CI] Event Count.•  Unsolicited adverse event reported at any time, until 28 days after the 2nd dose. |